AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology

By LabMedica International staff writers
Posted on 07 Apr 2026

Bone marrow aspirate examination is central to diagnosing and monitoring blood cancers and other serious hematologic diseases, yet the process in many laboratories remains manual and highly dependent on specialist expertise. Laboratories continue to seek standardized, efficient workflows that also enable remote collaboration and longitudinal review. A new artificial intelligence (AI)-enabled digital application now brings automated bone marrow morphology into laboratory workflows across the EMEA region.

Image: Laboratories in the EMEA region can now implement a digital, AI-assisted workflow for bone marrow morphology (photo courtesy of Cellavision)

The CellaVision Bone Marrow Aspirate (BMA) Application, recently introduced in EMEA, will be presented to the laboratory hematology community at the International Symposium on Technological Innovations in Laboratory Hematology (ISLH 2026) in Edinburgh from April 17–19. The application extends digital cell morphology into bone marrow aspirate analysis, one of the most complex areas in laboratory diagnostics. By digitizing key steps in bone marrow aspirate workflows, the application supports more standardized, efficient, and collaborative analysis.

The BMA Application received CE marking as a Class C product under the European Union In Vitro Diagnostic Regulation (EU IVDR) on December 8, 2025, confirming compliance with requirements for safety, performance, and quality. The launch is positioned as expanding access to digital marrow morphology within hematology workflows across the region.

Designed to deliver AI-assisted digital workflows, the CellaVision BMA Application digitizes key steps in bone marrow morphology. The system is intended to help laboratories automate, standardize, and simplify morphological examination while improving consistency and traceability of results. By reducing reliance on manual review, it addresses persistent variability in interpretation.

The CellaVision BMA Application operates on the CellaVision DC-1 analyzer using genuine 100× magnification. The software automatically identifies suitable analysis areas, captures high-resolution images, and pre-classifies nucleated cells into 17 morphologic cell types. CellaVision collaborates with Sysmex Corporation as a distribution partner for the BMA Application, building on established relationships with hospital and reference laboratories across the region.

The company will participate as a sponsor and exhibitor at ISLH 2026, taking place in Edinburgh from April 17–19, 2026, where it will present its latest innovations in digital cell morphology, including the BMA Application for the EMEA market.

“ISLH is an important meeting point for innovation in laboratory hematology,” says Peter Wilson, VP Global Marketing at CellaVision. “We look forward to demonstrating how our latest solutions support efficiency, consistency, and collaboration in both peripheral blood and bone marrow analysis."